Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication - PubMed (original) (raw)

Clinical Trial

Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication

F M Foss et al. Clin Lymphoma. 2001 Mar.

Abstract

DAB(389)IL-2 (denileukin diftitox, ONTAK) is a cytokine-targeted fusion protein that delivers the catalytic domain of diphtheria toxin to lymphoma cells expressing the interleukin-2 receptor (IL-2R). In phase I and phase III studies of DAB(389)IL-2 in patients with cutaneous T-cell lymphoma (CTCL), non-Hodgkin's lymphoma, and Hodgkin's disease in which premedications were limited to diphenhydramine and acetaminophen, acute infusion-related hypersensitivity reactions occurred in 70% of patients and vascular leak syndrome (VLS) in 27%, resulting in discontinuation of therapy in 29% of patients. There was no correlation between the dose or half-life of DAB(389)IL-2 and the occurrence of hypersensitivity events or VLS. To explore whether steroid premedication would improve the tolerability of DAB(389)IL-2, we treated 15 patients with CTCL with either dexamethasone or prednisone prior to each dose of DAB(389)IL-2. The incidence of acute infusion events was significantly decreased, with only three patients experiencing acute infusion events (one grade 4) and only two patients developing clinically apparent VLS. Grade 3 skin rash occurred in two patients and moderately severe asthenia in nine patients. A significantly improved response rate of 60% was noted with the use of steroid premedication compared to prior studies in which steroids were prohibited. We conclude that steroid premedication significantly improves the tolerability of DAB(389)IL-2 without compromising the clinical response.

PubMed Disclaimer

Cited by

Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.
Baldo BA, Pham NH. Baldo BA, et al. Cancer Metastasis Rev. 2013 Dec;32(3-4):723-61. doi: 10.1007/s10555-013-9447-3. Cancer Metastasis Rev. 2013. PMID: 24043487 Free PMC article. Review.
Menus for managing patients with cutaneous T-cell lymphoma.
Poligone B, Heald P. Poligone B, et al. Semin Cutan Med Surg. 2012 Mar;31(1):25-32. doi: 10.1016/j.sder.2011.12.002. Semin Cutan Med Surg. 2012. PMID: 22361286 Free PMC article. Review.
Immunotoxins for targeted cancer therapy.
Kreitman RJ. Kreitman RJ. AAPS J. 2006 Aug 18;8(3):E532-51. doi: 10.1208/aapsj080363. AAPS J. 2006. PMID: 17025272 Free PMC article. Review.
Therapy for mycosis fungoides.
Lundin J, Osterborg A. Lundin J, et al. Curr Treat Options Oncol. 2004 Jun;5(3):203-14. doi: 10.1007/s11864-004-0012-8. Curr Treat Options Oncol. 2004. PMID: 15115649 Review.
E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study.
Ohmachi K, Ando K, Ogura M, Uchida T, Tobinai K, Maruyama D, Namiki M, Nakanishi T. Ohmachi K, et al. Cancer Sci. 2018 Mar;109(3):794-802. doi: 10.1111/cas.13513. Epub 2018 Feb 26. Cancer Sci. 2018. PMID: 29363235 Free PMC article. Clinical Trial.

Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication - PubMed (original) (raw)